THE BENEFIT OF HER-2 TARGETED THERAPIES ON OVERALL SURVIVAL OF PATIENTS WITH METASTATIC BREAST CANCER – A SYSTEMATIC REVIEW
Author(s)
Alves C1, Mendes D1, Andrade S2, Batel Marques F3
1AIBILI, Coimbra, Portugal, 2Roche Farmaceutica Quimica, Amadora, Portugal, 3University of Coimbra, Coimbra, Portugal
OBJECTIVES: This study was aimed at evaluating the overall survival (OS) gains associated with HER-2 directed therapies in patients with metastatic breast cancer. METHODS: A bibliographic search was conducted in the MEDLINE (PubMed) and in the Cochrane Central Register of Controlled Trials databases, from their inception through March, 2014. Only phase III clinical trials (RCTs) including HER2-positive metastatic breast cancer patients have been included in this review, irrespective of the treatment administered (i.e., chemotherapy and/or hormone therapy, chemotherapy and/or hormone therapy plus HER2-targeted therapy). OS was defined as time from randomisation until the occurrence of death from any cause. Studies have been grouped according to the line of treatment, i.e. first-line or second-line or beyond. RESULTS: Seventeen RCTs were eligible for inclusion, of which 12 assessed therapies targeting metastatic breast cancer HER2+ in the first line setting. OS improved from 20.3 months in the first RCT (standard chemotherapy; Slamon et al, 2001) evaluating HER-2 targeting therapies to 48 months (estimated median OS) in the study of Swain and colleagues (2013), with triple combination of pertuzumab, trastuzumab and docetaxel. Four studies evaluated OS of HER-2 targeting therapies in second-line setting of metastatic breast cancer. The OS in second-line setting improved from 15.3 months (capecitabine; Cameron et al, 2008) to 30.7 months (trastuzumab emtancine; Verma et al, 2012). In the third-line setting, the association of lapatinib + trastuzumab has demonstrated to improve OS in 4.5 months compared with lapatinib alone (14 months vs 9.5 months; Blackwell et al, 2012). CONCLUSIONS: The HER-2 directed therapies had an undeniable benefic impact in the overall survival of patients with HER-2 positive metastatic breast cancer. Triple combination of docetaxel, pertuzumab and trastuzumab is associated with a survival extent of more than 3.5 years, compared with a life expectancy of 1,5 years achieved 13 years ago.
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PCN39
Topic
Clinical Outcomes
Topic Subcategory
Relating Intermediate to Long-term Outcomes
Disease
Oncology